Business

Organigram Receives Nasdaq Minimum Bid-Price Deficiency Notice

Marcus Lin
Add MyCannabis.com to your preferred sources on Google
Key PointsOrganigram must sustain a higher closing bid for an extended stretch rather than a…
View more
  • Organigram must sustain a higher closing bid for an extended stretch rather than a brief rebound.
  • Nasdaq staff can demand a longer compliance period and weigh trading volume and price trend.
  • A transfer to the Capital Market would extend time but not remove the underlying price test.

Organigram Global Inc. (OGI ) announced on November 13, 2026 that it received a Nasdaq deficiency notice on November 11, 2026, after its common shares closed below the US$1.00 minimum bid price for 30 consecutive business days.

The notice concerns the minimum bid-price requirement for continued listing on the Nasdaq Global Select Market. It has no immediate effect on the listing or trading of Organigram’s shares there, and it does not affect the company’s listing or compliance status on the Toronto Stock Exchange.

How Organigram Can Cure the Deficiency

Organigram has 180 calendar days from the notification, until May 10, 2027, to regain compliance under Nasdaq’s bid-price procedures. The closing bid must return to at least that threshold for a minimum of 10 consecutive business days during the compliance window.

The standard 10-business-day test is not necessarily the final measure. Nasdaq staff can require the company to meet the price requirement for more than 10 consecutive business days, generally no more than 20 consecutive business days, before determining that it has shown an ability to maintain long-term compliance. Staff may consider the margin by which the bid exceeds the requirement, trading volume, the number and size of market-maker quotations at or above the required price, and the trend of the share price.

If the First Window Expires

If Organigram has not regained compliance by the deadline, it may qualify for an additional 180-calendar-day period. That option is conditional on satisfying applicable requirements, including transferring its listing to the Nasdaq Capital Market. Nasdaq’s rules also require a transferring company to meet the applicable market-value requirement for publicly held shares and other Capital Market initial-listing standards except the bid-price requirement, based on its latest public filings and market information, and to notify Nasdaq of its intent to cure.

Without a cure or eligibility for more time, Nasdaq’s Listing Qualifications Department will issue a Staff Delisting Determination. Organigram could request review by a Hearings Panel, and the rules provide further appeal routes after that. A transfer would therefore change the listing venue and available time, not the underlying price test.

Aurora Transaction Remains Separate

Separately, Organigram is pursuing its acquisition of Aurora Cannabis (ACB ), announced on November 3, 2026. The agreement allows Aurora shareholders to elect C$7.80 in cash or 5.8626 Organigram shares for each Aurora share, or a mixed cash-and-share alternative, with elections subject to proration. The companies expect to complete the transaction in January 2027, subject to shareholder, court and regulatory approvals.

The immediate listing question is whether Organigram can produce a durable price recovery within the compliance window. A successful cure would resolve this specific deficiency; failure would make Capital Market eligibility and Nasdaq’s review procedures central to whether the shares retain their U.S. listing.

Marcus Lin is an AI-generated research agent for MyCannabis.com, covering cannabis companies, industry strategy, and market structure across regulated jurisdictions. His work focuses on how licensed producers, processors, and ancillary businesses operate within evolving regulatory environments—and how business decisions shape long-term market viability.

With a business-focused and analytical perspective, Marcus examines company strategy, consolidation trends, supply chain dynamics, and capital deployment across the cannabis sector. He places particular emphasis on execution, regulatory alignment, and the structural factors that determine whether companies can scale sustainably in legal markets.

Articles authored by Marcus Lin are AI-generated and reviewed by MyCannabis.com’s editorial team to ensure accuracy, context, and responsible coverage of cannabis industry developments in regulated markets.